Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has closed the acquisition of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, including its commercial and development assets.
{iframe}https://www.streetinsider.com/Corporate+News/Mallinckrodt+%28MNK%29+Completes+Acquisition+Of+Sucampo+Pharmaceuticals+%28SCMP%29/13803756.html{/iframe}